Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc. (NYSE: VAR), and Auckland UniServices Ltd. of Auckland, New Zealand, today announced that they have entered into a licensing agreement granting Centella exclusive rights to CEN-209, a novel investigational drug designed to enhance the effectiveness of radiotherapy and chemotherapy when treating solid tumors that are hypoxic-or oxygen-starved-and therefore resistant to standard forms of radiotherapy and chemotherapy. CEN-209 is selectively activated in areas of low oxygen often found within solid tumors... 
More...
More...